Pancragen
KEDW Tetrapeptide · Pancreas Bioregulator
Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.
Overview
Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.
Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Corrects age-related glucose tolerance disturbances in primate studies.
Reduces incidence and magnitude of metabolic syndrome.
Helps control blood sugar through pancreatic function support.
Impacts differentiation of pancreatic cells during aging.
Improves endocrine function of the pancreas.
Addresses age-related imbalance of pancreatic function.
Directly interacts with DNA to regulate pancreatic gene expression.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tetrapeptide bioregulator
- Chain length
- 4 residues
- Molecular weight
- 576 Da
- Typical dose
- 10-20mg daily
- Frequency
- Daily for 10-20 days per cycle
- Cycle length
- 10-20 days
- Storage
- Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated
Molecular data
- Type
- Tetrapeptide bioregulator
- Molecular weight
- 576 Da
- Chain length
- 4 residues
KEDWDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard protocol | Oral capsules | 10-20 mg | Daily for 10-20 days |
| Maintenance | Oral capsules | 10 mg | 2-3 cycles yearly |
| Research protocol | IM | 0.05 mg/kg | Daily for 10 days |
Interactions
Often combined in comprehensive anti-aging Khavinson protocols.
Different organ targets; can be used in comprehensive bioregulator protocols.
Part of Khavinson bioregulator family; targets different tissue.
Both affect glucose metabolism; interaction unknown.
Quality checklist
- ✓White powder or capsules
- ✓Clear solution if reconstituted
- ✓Proper packaging and labeling
- !Unknown source or purity
- ×Discoloration
- ×Unusual odor
- ×Damaged packaging
What to expect
Safety
- Generally well-tolerated
- Minimal side effects reported
- Allergic reactions
- Unusual blood sugar changes
- Signs of hypoglycemia
- Active pancreatic emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
- Type 1 diabetes (consult physician)
FAQ
Does Pancragen actually cure glucose intolerance, or just mask it?
Pancragen works through epigenetic regulation—it directly interacts with DNA to upregulate pancreatic transcription factors. In primate studies, it normalized insulin and C-peptide levels, suggesting actual restoration of pancreatic function rather than masking. However, this only works for age-related glucose tolerance decline, not for Type 1 diabetes or severe pancreatic damage.
Can I take Pancragen if I have Type 1 diabetes?
The contraindications specifically list Type 1 diabetes as requiring physician consultation. Type 1 involves autoimmune pancreatic destruction, which is different from the age-related metabolic decline Pancragen targets. Consult your endocrinologist before use—it's not appropriate for autoimmune pancreatic damage.
How long before Pancragen improves my blood sugar levels?
Pancragen works through gene expression changes, so results are cumulative. During the 10-20 day cycle, transcription factors are upregulated, but visible glucose improvements typically emerge over weeks to months. The file recommends 2-3 cycles yearly, suggesting ongoing cycles are needed for sustained benefits.
Should I monitor my blood sugar more closely while taking Pancragen?
Yes. The file specifically recommends blood glucose monitoring and HbA1c testing with long-term use. Since Pancragen improves insulin sensitivity and pancreatic function, your blood sugar may improve, which means you might need to adjust other diabetes medications to avoid hypoglycemia.